1
|
Nicol C, Jacquot J, Chebane L, Combret S, Pecquet PE, Massy N, Bagheri H. [Bariatric surgery and drugs: Review of the literature and Adverse Drug Reactions analysis in French National Pharmacovigilance Database]. Therapie 2024:S0040-5957(24)00033-7. [PMID: 38458944 DOI: 10.1016/j.therap.2024.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 02/09/2024] [Accepted: 02/22/2024] [Indexed: 03/10/2024]
Abstract
INTRODUCTION Bariatric surgery is the only treatment for severe obesity (BMI>35kg/m2) currently recognized as effective both in achieving tangible and lasting weight loss, and in improving obesity-related comorbidities such as type 2 diabetes, hypertension, and cardiovascular complications. Bariatric surgery, like any other surgery of the digestive tract, can have an impact on nutrient absorption, as well as on drug absorption. The literature on drug management in bariatric surgery patients concerned mainly of case reports and retrospective studies involving a small number of patients. No official guidelines are available. METHODS We conducted a literature search on the consequences of bariatric surgery in terms of drug bioavailability and/or effect. The Medline® (PubMed) database was searched using the following keywords: "bariatric surgery", "bioavailability", "gastric bypass", and "obesity". We completed this review with an analysis of reports of adverse drug reactions (ADRs) in post-bariatric surgery patients for obesity registered in the National pharmacovigilance database (PVDB). We selected all cases with the mention of "bariatric surgery and/or gastrectomy" as "medical history". After reading the cases, we excluded those in which the patient had undergone surgery for an indication other than obesity, where the route of administration was other than oral, and cases in which ADRs resulted from voluntary overdose, attempted suicide, allergy, switch to Levothyrox® new formulation, meningioma under progestative drugs, inefficacy related to generic substitution and medication error. RESULTS The literature search identified mainly "case report" about the impact of bariatric surgery on so-called "narrow therapeutic window" drugs. We identified 66 informative cases out of a total of 565 cases selected (11%) in the PVDB. Nevertheless, the information does not allow a clear relationship between the occurrence of the ADR and the influence of bariatric surgery. CONCLUSION There is a lack of official information and/or recommendations on medication use in subjects who have undergone bariatric surgery. Apart from under-reporting, ADRs reports remain largely uninformative. Health professional and patients would be awareness for improving, quantitatively and qualitatively the reporting of ADRs in this population.
Collapse
Affiliation(s)
- Carole Nicol
- Service de pharmacologie médicale, centre de pharmacovigilance de Toulouse, CIC1436, faculté de médecine, CHU de Toulouse, 31000 Toulouse, France
| | - Julien Jacquot
- Service de pharmacologie médicale, centre de pharmacovigilance de Toulouse, CIC1436, faculté de médecine, CHU de Toulouse, 31000 Toulouse, France
| | - Leila Chebane
- Service de pharmacologie médicale, centre de pharmacovigilance de Toulouse, CIC1436, faculté de médecine, CHU de Toulouse, 31000 Toulouse, France
| | - Sandrine Combret
- Centre régional de pharmacovigilance de Bourgogne, CHU de Dijon, 21000 Dijon, France
| | - Pauline-Eva Pecquet
- Service de pharmacologie clinique, centre de pharmacovigilance d'Amiens, CHU d'Amiens, 80000 Amiens, France
| | - Nathalie Massy
- Centre régional de pharmacovigilance de Rouen, CHU de Rouen, 76000 Rouen, France
| | - Haleh Bagheri
- Service de pharmacologie médicale, centre de pharmacovigilance de Toulouse, CIC1436, faculté de médecine, CHU de Toulouse, 31000 Toulouse, France.
| |
Collapse
|
2
|
Belliere J, Mazieres J, Meyer N, Chebane L, Despas F. Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. Diagnostics (Basel) 2021; 11:1187. [PMID: 34208848 PMCID: PMC8303282 DOI: 10.3390/diagnostics11071187] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Revised: 06/12/2021] [Accepted: 06/28/2021] [Indexed: 12/12/2022] Open
Abstract
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have unprecedentedly improved global prognosis in several types of cancers. However, they are associated with the occurrence of immune-related adverse events. Despite their low incidence, renal complications can interfere with the oncologic strategy. The breaking of peripheral tolerance and the emergence of auto- or drug-reactive T-cells are the main pathophysiological hypotheses to explain renal complications after ICI exposure. ICIs can induce a large spectrum of renal symptoms with variable severity (from isolated electrolyte disorders to dialysis-dependent acute kidney injury (AKI)) and presentation (acute tubule-interstitial nephritis in >90% of cases and a minority of glomerular diseases). In this review, the current trends in diagnosis and treatment strategies are summarized. The diagnosis of ICI-related renal complications requires special steps to avoid confounding factors, identify known risk factors (lower baseline estimated glomerular filtration rate, proton pump inhibitor use, and combination ICI therapy), and prove ICI causality, even after long-term exposure (weeks to months). A kidney biopsy should be performed as soon as possible. The treatment strategies rely on ICI discontinuation as well as co-medications, corticosteroids for 2 months, and tailored immunosuppressive drugs when renal response is not achieved.
Collapse
Affiliation(s)
- Julie Belliere
- Department of Nephrology and Organ Transplantation, University Hospital of Toulouse, 31 400 Toulouse, France
- INSERM U1048 (Institute of Metabolic and Cardiovascular Diseases), 31 400 Toulouse, France
- Department of Biological Sciences, Paul Sabatier University, 31 400 Toulouse, France; (J.M.); (N.M.)
| | - Julien Mazieres
- Department of Biological Sciences, Paul Sabatier University, 31 400 Toulouse, France; (J.M.); (N.M.)
- Institut Universitaire du Cancer Toulouse Oncopole, 31 400 Toulouse, France
- Department of Pneumology, University Hospital of Toulouse, 31 400 Toulouse, France
| | - Nicolas Meyer
- Department of Biological Sciences, Paul Sabatier University, 31 400 Toulouse, France; (J.M.); (N.M.)
- Institut Universitaire du Cancer Toulouse Oncopole, 31 400 Toulouse, France
- Department of Dermatology, University Hospital of Toulouse, 31 400 Toulouse, France
| | - Leila Chebane
- Service Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, 31 400 Toulouse, France; (L.C.); (F.D.)
| | - Fabien Despas
- Service Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, 31 400 Toulouse, France; (L.C.); (F.D.)
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université Paul Sabatier, Equipe PEPSS Centre d’Investigation Clinique 1436, INSERM 1297, 31 400 Toulouse, France
| |
Collapse
|
3
|
Gainville A, Rousseau V, Kaguelidou F, Gervoise MB, Michot J, Pizzoglio-Bellaudaz V, Chebane L, Weckel A, Montastruc JL, Durrieu G. Drug-Induced Hearing Loss in Children: An Analysis of Spontaneous Reports in the French PharmacoVigilance Database. Paediatr Drugs 2021; 23:87-93. [PMID: 33200354 DOI: 10.1007/s40272-020-00425-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/24/2020] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Hearing loss can have a negative impact on communication, with significant vocational, educational, and social consequences. Drugs are one of the causes of hearing loss in children. OBJECTIVES The objective of our study was to describe drug-induced hearing loss in the pediatric population. METHODS Reports of hearing loss from 1985 to December 2019 in the pediatric population (< 18 years) were extracted from the French PharmacoVigilance Database (FPVD). We performed a retrospective and descriptive analysis of adverse drug reaction (ADR) reports. RESULTS A total of 70 ADR reports were identified among the 51,216 reports registered in the FPVD, 37 involving adolescents (12-17 years, 52.9%), 28 children (2-11 years, 40.0%), and 5 infants (28 days-23 months, 7.1%). Overall, 40 reports (57.1%) involved girls. A total of 56 reports (80.0%) were "serious." The most frequent hearing disorders were deafness (n = 31, 44.3%) and hypoacusis (n = 22, 31.4%). Suspected drugs (ATC 5th level) were amikacin (n = 11, 15.7%), cisplatin (n = 11, 15.7%), doxorubicin (n = 4, 5.7%), vincristine (n = 4, 5.7%), clarithromycin (n = 4, 5.7%), ceftriaxone (n = 3, 4.3%), isotretinoin (n = 3, 4.3%), and vancomycin (n = 3, 4.3%). CONCLUSIONS This study shows that about three out of four cases of drug-induced hearing loss in the pediatric population were "serious". It also underlines the under-reporting of these ADRs and the importance of strengthening hearing monitoring in children during and long after drug exposure.
Collapse
Affiliation(s)
- Adrien Gainville
- Service de Pharmacologie Médicale et Clinique, Centre Régional de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, INSERM U 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, France, 37 Allées Jules Guesde, 31000, Toulouse, France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique, Centre Régional de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, INSERM U 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, France, 37 Allées Jules Guesde, 31000, Toulouse, France
| | - Florentia Kaguelidou
- Centre d'Investigation Clinique, INSERM CIC1426, Hôpital Robert Debré, 48, boulevard Sérurier, 75019, Paris, France
| | - Marie Boyer Gervoise
- Service de pharmacologie clinique et pharmacovigilance, centre régional de pharmacovigilance Marseille Provence Corse, hôpital Sainte-Marguerite, Hôpitaux de Marseille, 13009, Marseille, France
| | - Joëlle Michot
- Centre Régional de Pharmacovigilance, Saint Antoine Hôpital (APHP), Paris, France
| | - Véronique Pizzoglio-Bellaudaz
- Service Hospitalo-Universitaire de Pharmacotoxicologie, Centre de Pharmacovigilance, Hospices Civils de Lyon, CHU-Lyon, Lyon, France
| | - Leila Chebane
- Service de Pharmacologie Médicale et Clinique, Centre Régional de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, INSERM U 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, France, 37 Allées Jules Guesde, 31000, Toulouse, France
| | - Alexandra Weckel
- Service d'ORL pédiatrique, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Jean-Louis Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Régional de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, INSERM U 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, France, 37 Allées Jules Guesde, 31000, Toulouse, France
| | - Geneviève Durrieu
- Service de Pharmacologie Médicale et Clinique, Centre Régional de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, INSERM U 1027, CIC INSERM 1436, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, France, 37 Allées Jules Guesde, 31000, Toulouse, France.
| |
Collapse
|
4
|
Touafchia D, Montastruc F, Lapeyre-Mestre M, Rousseau V, Chebane L, Revet A. Drug-induced tics: An observational postmarketing study. Hum Psychopharmacol 2020; 35:e2734. [PMID: 32352603 DOI: 10.1002/hup.2734] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Revised: 03/29/2020] [Accepted: 03/30/2020] [Indexed: 11/10/2022]
Abstract
OBJECTIVES While drug-induced tics have been described, in particular with neuroleptics, psychostimulants, or anti-epileptics, the strength and the direction of these associations are still debated. The aim of this study was to investigate the association between tics and drug exposure through a two-step analysis in two pharmacovigilance databases. METHODS We first performed a descriptive clinical analysis of cases registered in the French pharmacovigilance database (FPVD) from January 1985 to December 2018. We then performed a disproportionality analysis in VigiBase®, the WHO pharmacovigilance database, from January 1967 to June 2019, through the calculation of reporting odds ratio (ROR). RESULTS The drugs most frequently associated with tics in the FPVD were methylphenidate, lamotrigine, montelukast, tramadol, mirtazapine, venlafaxine, aripiprazole, and risperidone. In VigiBase®, we found a significant ROR with methylphenidate (ROR 37.54, 95% confidence interval [CI] 34.81-40.48), montelukast (ROR 12.18, 95% CI 10.29-14.41), aripiprazole (ROR 7.40, 95% CI 6.35-8.62), risperidone (ROR 4.40, 95% CI 3.72-5.21), and venlafaxine (ROR 1.52, 95% CI 1.14-2.03). CONCLUSION This postmarketing study confirmed a potential harmful association with methylphenidate (the highest association, as expected), aripiprazole, risperidone, lamotrigine, and venlafaxine and, interestingly, found a strong signal with montelukast, which, to our knowledge, had never been published before.
Collapse
Affiliation(s)
- Davy Touafchia
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France
| | - François Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France.,UMR 1027 Inserm, Université Toulouse III, Toulouse, France.,CIC 1436 CHU de Toulouse, Toulouse, France
| | - Maryse Lapeyre-Mestre
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France.,UMR 1027 Inserm, Université Toulouse III, Toulouse, France.,CIC 1436 CHU de Toulouse, Toulouse, France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France
| | - Leila Chebane
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France
| | - Alexis Revet
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France.,UMR 1027 Inserm, Université Toulouse III, Toulouse, France.,Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, CHU de Toulouse, Toulouse, France
| |
Collapse
|
5
|
Barthez S, Revet A, Chouchana L, Jonville-Bera AP, Pizzoglio V, Raynaud JP, Chebane L, Lapeyre-Mestre M, Montastruc F. Adverse drug reactions in infants, children and adolescents exposed to antidepressants: a French pharmacovigilance study. Eur J Clin Pharmacol 2020; 76:1591-1599. [DOI: 10.1007/s00228-020-02944-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Accepted: 06/19/2020] [Indexed: 12/22/2022]
|
6
|
de Canecaude C, Rousseau V, Chebane L, Lafaurie M, Durrieu G, Montastruc JL. Can tramadol really induce hyponatraemia? A pharmacovigilance study. Br J Clin Pharmacol 2020; 87:683-686. [PMID: 32470196 DOI: 10.1111/bcp.14401] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 05/14/2020] [Accepted: 05/16/2020] [Indexed: 12/16/2022] Open
Abstract
Several papers have described hyponatraemia with tramadol. However, in most reports, several confounding factors can be found. We used the WHO pharmacovigilance database (VigiBase®) to investigate if tramadol alone could be associated with hyponatraemia. All 1992-2019 ICSRs (individual case safety reports) with the preferred term (PT) "hyponatraemia" and tramadol were included. Two disproportionality analyses were performed: (1) after inclusion of all reports, and (2) after exclusion of concomitant hyponatraemic drugs. Results are expressed as reporting odds ratios (ROR; 95% CI) and information component (IC). Of 19 747 604 ICSRs, 225 575 were included. A significant association was found between tramadol use and reports of hyponatraemia (ROR = 1.49 [1.39-1.60], IC = 0.57 [IC025 = 0.47]). After exclusion of hyponatraemic drugs, the previously found association disappeared. The study failed to find any pharmacovigilance signal of hyponatraemia with tramadol alone. We suggest that reports of hyponatraemia with tramadol can be explained principally by other underlying causes of hyponatraemia, especially other concomitant hyponatraemic drugs.
Collapse
Affiliation(s)
- Claire de Canecaude
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament, INSERM UMR 1027, CIC 1426, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament, INSERM UMR 1027, CIC 1426, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, France
| | - Leila Chebane
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament, INSERM UMR 1027, CIC 1426, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, France
| | - Margaux Lafaurie
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament, INSERM UMR 1027, CIC 1426, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, France
| | - Geneviève Durrieu
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament, INSERM UMR 1027, CIC 1426, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, France
| | - Jean-Louis Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance de Pharmacoépidémiologie et d'Informations sur le Médicament, INSERM UMR 1027, CIC 1426, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, France
| |
Collapse
|
7
|
Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL. Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study". Mov Disord 2020; 35:376-377. [PMID: 32056308 DOI: 10.1002/mds.27956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Accepted: 11/25/2019] [Indexed: 11/07/2022] Open
Affiliation(s)
- Tatiana Pacheco-Paez
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,Department of Clinical Pharmacology, Evidence-Based Therapeutics Group, Universidad de La Sabana, Chía, Colombia
| | - François Montastruc
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426-University Paul Sabatier Toulouse, Toulouse, France
| | - Vanessa Rousseau
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426-University Paul Sabatier Toulouse, Toulouse, France
| | - Leila Chebane
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France
| | - Maryse Lapeyre-Mestre
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426-University Paul Sabatier Toulouse, Toulouse, France
| | - Christel Renoux
- Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Québec, Canada.,Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada
| | - Jean-Louis Montastruc
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426-University Paul Sabatier Toulouse, Toulouse, France
| |
Collapse
|
8
|
Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL. Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study. Mov Disord 2019; 35:176-180. [PMID: 31633228 DOI: 10.1002/mds.27876] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 08/22/2019] [Accepted: 09/04/2019] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Use of gabapentinoids is increasing. Following recent case reports, we investigated a putative risk of parkinsonism with pregabalin or gabapentin. METHODS A disproportionality analysis of 5,653,547 individual case safety reports in the World Health Organization individual case safety report database, VigiBase, compared all patients with parkinsonism who were receiving gabapentinoids with other patients. Results are shown as reporting odds ratios and the information component, an indicator of disproportionate Bayesian reporting. Sensitivity analyses included comparisons with drugs used for similar indications (amitriptyline, duloxetine) and exclusion of drugs that induce parkinsonism. RESULTS Among 5,653,547 reports, 4925 parkinsonism reports were found with pregabalin and 4881 with gabapentin. Gabapentin and pregabalin were associated with increased reporting odds ratio (2.16 [2.10-2.23], 2.43 [2.36-2.50]). Similar trends were found using information components after excluding drugs that induce parkinsonism and for pregabalin compared with amitriptyline or duloxetine. CONCLUSIONS This study found that gabapentinoids (particularly pregabalin) can be associated with parkinsonism. © 2019 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Tatiana Pacheco-Paez
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,Department of Clinical Pharmacology, Evidence-Based Therapeutics Group, Universidad de La Sabana, Chía, Colombia
| | - François Montastruc
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France
| | - Vanessa Rousseau
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France
| | - Leila Chebane
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France
| | - Maryse Lapeyre-Mestre
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France
| | - Christel Renoux
- Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Québec, Canada.,Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada
| | - Jean-Louis Montastruc
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France
| |
Collapse
|
9
|
Sabatier P, Amar J, Montastruc F, Rousseau V, Chebane L, Bouhanick B, Montastruc JL. Breast cancer and spironolactone: an observational postmarketing study. Eur J Clin Pharmacol 2019; 75:1593-1598. [DOI: 10.1007/s00228-019-02740-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Accepted: 08/09/2019] [Indexed: 10/26/2022]
|
10
|
Montastruc F, Benevent J, Chebane L, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBase®. Eur J Clin Pharmacol 2018; 74:1673-1674. [PMID: 30094704 DOI: 10.1007/s00228-018-2536-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 08/03/2018] [Indexed: 11/26/2022]
Affiliation(s)
- François Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- CIC 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Justine Benevent
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| | - Leila Chebane
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- CIC 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Geneviève Durrieu
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Agnès Sommet
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- CIC 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Jean-Louis Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Toulouse, France.
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France.
- CIC 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
| |
Collapse
|
11
|
Montastruc G, Benevent J, Rousseau V, Chebane L, Bondon-Guitton E, Durrieu G, Montastruc J, Montastruc F, Sommet A. Statins and diabetes: Are all statins at risk? A pharmacoepidemiological study. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, Montastruc F, Montastruc JL. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl) 2017; 234:3075-3081. [PMID: 28770276 DOI: 10.1007/s00213-017-4685-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Accepted: 07/05/2017] [Indexed: 01/08/2023]
Abstract
BACKGROUND QT interval prolongations were described with citalopram and escitalopram. However, the effects of the other serotonin reuptake inhibitors (SRIs) remained discussed. In order to identify a putative signal with other SRIs, the present study investigates the reports of QT interval prolongation with SRIs in two pharmacovigilance databases (PVDB). METHODS Two kinds of investigations were performed: (1) a comparative study in VigiBase®, the WHO PVDB, where notifications of QT prolongation with six SRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) were selected. Cases with overdose or pregnancy were excluded. The relationship between the "suspected" SRI and occurrence of QT prolongation was assessed by calculating reporting odds ratio (ROR) in a case/non-case design. (2) A descriptive study of QT prolongation reports with citalopram and escitalopram in the French FPVD. RESULTS In VigiBase®, 855 notifications were identified (mean age 56.2 years, mainly women 73%). Among them, 172 (20.1%) were associated to escitalopram; 299 (35.0%), to citalopram; 186 (21.8%), to fluoxetine; 94 (11.0%), to sertraline; 66 (7.7%), to paroxetine; and 38 (4.4%) to fluvoxamine. A significant ROR value (higher than 1) was only found for citalopram (3.35 CI95% [2.90-3.87]) or escitalopram (2.50 [2.11-2.95]). In the FPVD, eight reports of QT prolongation were found with citalopram and 27 with escitalopram, mainly in women (77.1%) with a mean age of 73.2 years. In 23 cases (66%), SRIs were associated with other suspected drugs, mainly cardiotropic or psychotropic ones. Hypokalemia was associated in six patients. CONCLUSION This study, performed in real conditions of life, shows a clear signal of QT prolongation with only two SRIs, citalopram and escitalopram, indicating that QT prolongation is not a SRI class effect.
Collapse
Affiliation(s)
- Ana Ojero-Senard
- Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, CHU et Faculté de Médecine de Toulouse, Toulouse, France
| | - Justine Benevent
- Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, CHU et Faculté de Médecine de Toulouse, Toulouse, France
| | - Emmanuelle Bondon-Guitton
- Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, CHU et Faculté de Médecine de Toulouse, Toulouse, France
| | - Geneviève Durrieu
- Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, CHU et Faculté de Médecine de Toulouse, Toulouse, France
| | - Leila Chebane
- Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, CHU et Faculté de Médecine de Toulouse, Toulouse, France
| | - Melanie Araujo
- Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, CHU et Faculté de Médecine de Toulouse, Toulouse, France
| | - Francois Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, CHU et Faculté de Médecine de Toulouse, Toulouse, France
| | - Jean-Louis Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, CHU et Faculté de Médecine de Toulouse, Toulouse, France.
| |
Collapse
|
13
|
Montastruc F, Benevent J, Touafchia A, Chebane L, Araujo M, Guitton-Bondon E, Durrieu G, Arbus C, Schmitt L, Begaud B, Montastruc JL. Atropinic (anticholinergic) burden in antipsychotic-treated patients. Fundam Clin Pharmacol 2017; 32:114-119. [DOI: 10.1111/fcp.12321] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Revised: 08/01/2017] [Accepted: 08/31/2017] [Indexed: 11/30/2022]
Affiliation(s)
- François Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de PharmacoVigilance; de Pharmacoépidémiologie et d'Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; INSERM UMR 1027; CIC INSERM 1436; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
- Département de Pharmacologie Médicale; INSERM U 1219 “Médicaments et Santé des Populations”; Université de Bordeaux; Bordeaux France
| | - Justine Benevent
- Laboratoire de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de PharmacoVigilance; de Pharmacoépidémiologie et d'Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; INSERM UMR 1027; CIC INSERM 1436; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| | - Anthony Touafchia
- Laboratoire de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de PharmacoVigilance; de Pharmacoépidémiologie et d'Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; INSERM UMR 1027; CIC INSERM 1436; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| | - Leila Chebane
- Laboratoire de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de PharmacoVigilance; de Pharmacoépidémiologie et d'Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; INSERM UMR 1027; CIC INSERM 1436; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| | - Mélanie Araujo
- Laboratoire de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de PharmacoVigilance; de Pharmacoépidémiologie et d'Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; INSERM UMR 1027; CIC INSERM 1436; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| | - Emmanuelle Guitton-Bondon
- Laboratoire de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de PharmacoVigilance; de Pharmacoépidémiologie et d'Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; INSERM UMR 1027; CIC INSERM 1436; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| | - Geneviève Durrieu
- Laboratoire de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de PharmacoVigilance; de Pharmacoépidémiologie et d'Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; INSERM UMR 1027; CIC INSERM 1436; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| | - Christophe Arbus
- Service Hospitalo-Universitaire de Psychiatrie et de Psychologie Médicale; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| | - Laurent Schmitt
- Service Hospitalo-Universitaire de Psychiatrie et de Psychologie Médicale; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| | - Bernard Begaud
- Département de Pharmacologie Médicale; INSERM U 1219 “Médicaments et Santé des Populations”; Université de Bordeaux; Bordeaux France
| | - Jean-Louis Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de PharmacoVigilance; de Pharmacoépidémiologie et d'Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; INSERM UMR 1027; CIC INSERM 1436; Faculté de Médecine de Toulouse; Centre Hospitalier Universitaire; Toulouse France
| |
Collapse
|
14
|
Linselle M, Sommet A, Bondon-Guitton E, Moulis F, Durrieu G, Benevent J, Rousseau V, Chebane L, Bagheri H, Montastruc F, Montastruc JL. Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase ® , the WHO pharmacovigilance database. Fundam Clin Pharmacol 2017; 31:359-366. [PMID: 28036099 DOI: 10.1111/fcp.12264] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Revised: 12/14/2016] [Accepted: 12/28/2016] [Indexed: 11/30/2022]
Abstract
The potential favorizing role of drugs in sleep apnea syndrome (SAS) is unknown. This study investigates drugs associated with SAS in a pharmacovigilance database. SAS recorded as adverse drug reactions (ADRs) in VigiBase® , the WHO pharmacovigilance database (more than 11 million reports), from 1978 to 2015 was selected. The risk of SAS reports was estimated using the case-noncase method, with cases being SAS and noncases all other recorded ADRs. During this 37-year period, 3325 ADRs including the word SAS were registered (0.05% of the database). Mean age was 51.2 ± 16.9 years with 52% men. ADRs were 'serious' in around 82% of cases. The case-noncase study found an association between SAS and exposition with sodium oxybate, rofecoxib, quetiapine, and clozapine for individual drugs and coxibs, antipsychotics, benzodiazepines, and opium alkaloids for drug classes. The potential role of other drugs is discussed. This study suggests that SAS can be associated with some drugs (mainly psychotropics) that are able to reveal or aggravate such a disease. Physicians should take into account the role of drugs in the etiological appraisal and management of SAS.
Collapse
Affiliation(s)
- Mélanie Linselle
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Agnès Sommet
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Emmanuelle Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Florence Moulis
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Geneviève Durrieu
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Justine Benevent
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Leila Chebane
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Haleh Bagheri
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - François Montastruc
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| | - Jean-Louis Montastruc
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Equipe de Pharmacoépidémiologie de l'INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France
| |
Collapse
|
15
|
Montastruc F, Moulis F, Araujo M, Chebane L, Rascol O, Montastruc JL. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease. Eur J Clin Pharmacol 2016; 73:99-103. [PMID: 27796464 DOI: 10.1007/s00228-016-2142-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 09/27/2016] [Indexed: 11/24/2022]
Abstract
PURPOSE Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years. METHODS A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016. The signal of disproportionality was calculated using reporting odds ratios (ROR). In our study, 154 ICSRs of heart failure occurring in 154 Parkinsonian patients (mean age 69.6 years, 51 % women) treated with DA agonists were included. RESULTS AND CONCLUSION There was a significant signal between occurrence of heart failure and exposure to pergolide or cabergoline in particular and ergot derivatives in general. In contrast, none signal was found for rotigotine, pramipexole, apomorphine, or ropinirole in particular and non-ergot derivatives in general. The present study underlines the importance to prescribe as DA agonists in Parkinsonian patients only non-ergot derivatives, excluding ergot drugs.
Collapse
Affiliation(s)
- François Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France
- CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France
| | - Florence Moulis
- Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Mélanie Araujo
- Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Leila Chebane
- Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Olivier Rascol
- Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France
- INSERM UMR 825, Université de Toulouse, Toulouse, France
| | - Jean-Louis Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
- INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France.
- CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
- NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France.
| |
Collapse
|
16
|
Abstract
Many patients treated with imatinib, used in cancer treatment, are using several other drugs that could interact with imatinib. Our aim was to study all the drug-drug interactions (DDIs) observed in patients treated with imatinib.We performed 2 observational studies, between the 1st January 2012 and the 31st August 2015 in the Midi-Pyrénées area (South Western France), using the French health insurance reimbursement database and then the French Pharmacovigilance Database (FPVD).A total of 544 patients received at least 1 reimbursement for imatinib. Among them, 486 (89.3%) had at least 1 drug that could potentially interact with imatinib. Paracetamol was the most frequent drug involved (77.4%). Proton pump inhibitors, dexamethasone and levothyroxine, were found in >10% of patients. In the FPVD, among a total of 25 reports of ADRs with imatinib recorded in the Midi-Pyrénées area, 10 (40%) had potential DDIs with imatinib. Imatinib was most frequently prescribed by hospital physicians and drugs interacting with imatinib, by general practitioners.Our study showed that at least 40% of the patients treated with imatinib were at risk of DDIs and that all prescribers must be cautious with DDIs in patients treated with imatinib. During imatinib treatment, we particularly recommend to limit the dose of paracetamol at 1300 mg per day, to avoid the use of dexamethasone, and to double the dose of levothyroxine.
Collapse
Affiliation(s)
- Isabelle Récoché
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l’Université de Toulouse and Service de Pharmacologie Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d’Informations sur le Médicament, Centre Hospitalier Universitaire
| | - Vanessa Rousseau
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l’Université de Toulouse and Service de Pharmacologie Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d’Informations sur le Médicament, Centre Hospitalier Universitaire
| | - Robert Bourrel
- Echelon Régional du Service Médical de la CNAM-TS Midi-Pyrénées
| | - Maryse Lapeyre-Mestre
- Laboratoire de Pharmacologie Médicale et Clinique, Equipe de PharmacoEpidémiologie, Faculté de Médecine de l’Université de Toulouse and Service de Pharmacologie Clinique, Centre Hospitalier Universitaire, Toulouse, France
| | - Leila Chebane
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l’Université de Toulouse and Service de Pharmacologie Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d’Informations sur le Médicament, Centre Hospitalier Universitaire
| | - Fabien Despas
- Laboratoire de Pharmacologie Médicale et Clinique, Equipe de PharmacoEpidémiologie, Faculté de Médecine de l’Université de Toulouse and Service de Pharmacologie Clinique, Centre Hospitalier Universitaire, Toulouse, France
| | - Jean-Louis Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l’Université de Toulouse and Service de Pharmacologie Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d’Informations sur le Médicament, Centre Hospitalier Universitaire
| | - Emmanuelle Bondon-Guitton
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l’Université de Toulouse and Service de Pharmacologie Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d’Informations sur le Médicament, Centre Hospitalier Universitaire
- Correspondence: Emmanuelle Bondon-Guitton, Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Toulouse, France (e-mail: )
| |
Collapse
|
17
|
Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Montastruc F. Neurological and digestive bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists: The differences do not stop there! A pharmacovigilance study. Pharmacol Res 2016; 118:119-120. [PMID: 27265115 DOI: 10.1016/j.phrs.2016.05.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 05/24/2016] [Accepted: 05/25/2016] [Indexed: 10/21/2022]
Affiliation(s)
- A Cabarrot
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France.
| | - J L Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - L Chebane
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - V Rousseau
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - E Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - F Moulis
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - G Durrieu
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - H Bagheri
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - F Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| |
Collapse
|
18
|
De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F. Atropinic (Anticholinergic) Burden in Parkinson's Disease. Mov Disord 2016; 31:632-6. [DOI: 10.1002/mds.26595] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Accepted: 02/03/2016] [Indexed: 11/09/2022] Open
Affiliation(s)
- Sibylle De Germay
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
- INSERM UMR 1027, Faculté de Médecine; Université de Toulouse; Toulouse France
| | - Jean-Louis Montastruc
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
- INSERM UMR 1027, Faculté de Médecine; Université de Toulouse; Toulouse France
- CIC INSERM 1436; Université et Centre Hospitalier Universitaire de Toulouse; Toulouse France
- NeuroToul Centre of Excellence in Neurodegeneration; Université et Centre Hospitalier Universitaire; France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
- INSERM UMR 1027, Faculté de Médecine; Université de Toulouse; Toulouse France
- CIC INSERM 1436; Université et Centre Hospitalier Universitaire de Toulouse; Toulouse France
| | - Leila Chebane
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
| | - Emmanuelle Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
- INSERM UMR 1027, Faculté de Médecine; Université de Toulouse; Toulouse France
| | - Florence Moulis
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
| | - Genevieve Durrieu
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
| | - Haleh Bagheri
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
- INSERM UMR 1027, Faculté de Médecine; Université de Toulouse; Toulouse France
- NeuroToul Centre of Excellence in Neurodegeneration; Université et Centre Hospitalier Universitaire; France
| | - Olivier Rascol
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- CIC INSERM 1436; Université et Centre Hospitalier Universitaire de Toulouse; Toulouse France
- NeuroToul Centre of Excellence in Neurodegeneration; Université et Centre Hospitalier Universitaire; France
- INSERM UMR 825; Université de Toulouse; Toulouse France
| | - Antoine Pariente
- Département de Pharmacologie; Université et Centre Hospitalier Universitaire de Bordeaux; Bordeaux France
- INSERM U 657, Pharmacoepidemiology; Université et Centre Hospitalier Universitaire de Bordeaux; Bordeaux France
| | - Bernard Bégaud
- Département de Pharmacologie; Université et Centre Hospitalier Universitaire de Bordeaux; Bordeaux France
- INSERM U 657, Pharmacoepidemiology; Université et Centre Hospitalier Universitaire de Bordeaux; Bordeaux France
| | - François Montastruc
- Service de Pharmacologie Médicale et Clinique; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; Toulouse France
- Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées; Centre Hospitalier Universitaire de Toulouse; Toulouse France
- INSERM UMR 1027, Faculté de Médecine; Université de Toulouse; Toulouse France
- CIC INSERM 1436; Université et Centre Hospitalier Universitaire de Toulouse; Toulouse France
- NeuroToul Centre of Excellence in Neurodegeneration; Université et Centre Hospitalier Universitaire; France. Département de Pharmacologie; Université et Centre Hospitalier Universitaire de Bordeaux; Bordeaux France
| |
Collapse
|
19
|
Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, Baldin B, Pugnet G, Montastruc JL, Bagheri H. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam Clin Pharmacol 2015; 30:162-71. [DOI: 10.1111/fcp.12171] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 10/27/2015] [Accepted: 11/17/2015] [Indexed: 12/17/2022]
Affiliation(s)
- Layla Saliba
- Service de Pharmacologie Medicale et Clinique; Centre Midi-Pyrenees de PharmacoVigilance; de Pharmacoepidemiologie et d'Informations sur le Medicament; 37 allées Jules Guesde 31000 Toulouse France
- INSERM; UMR 1027; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| | - Guillaume Moulis
- INSERM; UMR 1027; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
- Service de Médecine Interne; Centre Hospitalier Universitaire de Toulouse; Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9; France
| | - Malak Abou Taam
- Centre Régional de PharmacoVigilance; Centre Hospitalier Universitaire de Reims; Avenue du Général Koenig 51092 Reims France
| | - Vanessa Rousseau
- Service de Pharmacologie Medicale et Clinique; Centre Midi-Pyrenees de PharmacoVigilance; de Pharmacoepidemiologie et d'Informations sur le Medicament; 37 allées Jules Guesde 31000 Toulouse France
| | - Leila Chebane
- Service de Pharmacologie Medicale et Clinique; Centre Midi-Pyrenees de PharmacoVigilance; de Pharmacoepidemiologie et d'Informations sur le Medicament; 37 allées Jules Guesde 31000 Toulouse France
| | - Nadine Petitpain
- Centre Régional de PharmacoVigilance; Centre Hospitalier Universitaire de Nancy; 29 avenue du Maréchal de Lattre de Tassigny 54035 Nancy cedex France
| | - Bernadette Baldin
- Centre Régional de PharmacoVigilance; Hôpital de Cimiez BP 1179; 06003 Nice cedex 1 France
| | - Grégory Pugnet
- INSERM; UMR 1027; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
- Service de Médecine Interne; Centre Hospitalier Universitaire de Toulouse; Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9; France
| | - Jean-Louis Montastruc
- Service de Pharmacologie Medicale et Clinique; Centre Midi-Pyrenees de PharmacoVigilance; de Pharmacoepidemiologie et d'Informations sur le Medicament; 37 allées Jules Guesde 31000 Toulouse France
- INSERM; UMR 1027; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| | - Haleh Bagheri
- Service de Pharmacologie Medicale et Clinique; Centre Midi-Pyrenees de PharmacoVigilance; de Pharmacoepidemiologie et d'Informations sur le Medicament; 37 allées Jules Guesde 31000 Toulouse France
- INSERM; UMR 1027; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| |
Collapse
|
20
|
Berreni A, Montastruc F, Bondon-Guitton E, Rousseau V, Abadie D, Durrieu G, Chebane L, Giroud JP, Bagheri H, Montastruc JL. Adverse drug reactions to self-medication: a study in a pharmacovigilance database. Fundam Clin Pharmacol 2015. [DOI: 10.1111/fcp.12140] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Aurélia Berreni
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
| | - François Montastruc
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
| | - Emmanuelle Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
| | - Delphine Abadie
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
| | - Geneviève Durrieu
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
| | - Leila Chebane
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
| | - Jean-Paul Giroud
- Académie Nationale de Médecine; 16 Rue Bonaparte 75272 Paris France
| | - Haleh Bagheri
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
| | - Jean-Louis Montastruc
- Service de Pharmacologie Médicale et Clinique; Centre Midi-Pyrénées de Pharmacovigilance; Pharmacoépidémiologie et Informations sur le Médicament; Pharmacopôle Midi-Pyrénées; CIC INSERM 1436; Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse; 37 Allées Jules-Guesde Toulouse 31000 France
- Académie Nationale de Médecine; 16 Rue Bonaparte 75272 Paris France
| |
Collapse
|
21
|
Guinard E, Bulai Livideanu C, Chebane L, Bagheri H, Lahfa M, Marguery M, Hautier Mazereeuw J, Cogny N, Blancher A, Paul C. Tuberculose active chez patients psoriasis traités par anti-TNF alpha : faut-il se méfier des résultats biologiques négatifs ? Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Chebane L, Tavassoli N, Bagheri H, Montastruc JL. [Drug-induced hyperglycemia: a study in the French pharmacovigilance database]. Therapie 2010; 65:447-58. [PMID: 21144480 DOI: 10.2515/therapie/2010051] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2009] [Accepted: 03/01/2010] [Indexed: 12/28/2022]
Abstract
OBJECTIVE To analyse drugs inducing hyperglycemia by using data reported to the French spontaneous reporting system and recorded in the French PharmacoVigilance Database (FPVD). METHODS All cases with a report of hyperglycemia and/or diabetes in the French database between 1985 and 2008 were included in the study. We estimated the risk of hyperglycemia linked to drugs by the case/non-case method. Cases were reports including hyperglycemia and non cases all other reports. This risk was estimated through calculation of reporting odds ratios (ROR). RESULTS During this period, 1219 reports including the words "hyperglycemia and/or diabetes" were registered (0.34% of the database). This adverse drug reaction occurred 1 fold over 4 in diabetics or as a part of HIV infection. Effect was "serious" in approximatively 50% of cases. We found an increase of risk during exposition with methylprednisolone [ROR=43.5; 95% CI (37.3-50.8)], tacrolimus [ROR=25; 95% CI (17.9-34.8)], olanzapine [ROR=19.9; 95% CI (14.9-26.5)], prednisone [ROR=18.9; 95% CI (15.7-22.8)] or pentamidine [ROR=15.4; 95% CI (8.2-28.3)]. CONCLUSION Drug classes most frequently found in FPVD linked to hyperglycemia are antiretroviral, steroidal anti-inflammatory, second generation neuroleptic, immunosuppressive and diuretic drugs.
Collapse
Affiliation(s)
- Leila Chebane
- Laboratoire de Pharmacologie Médicale et Clinique, Unité de Pharmacoépidémiologie EA 3696, Université de Toulouse, Faculté de Médecine, Toulouse, France
| | | | | | | | | |
Collapse
|